

CURRICULUM VITAE

February 2008

NAME: Nancy J. Olsen, M.D.

PRESENT POSITION: Professor of Internal Medicine
McGee Foundation Chair in Arthritis Research
Director of Clinical Research, Simmons Arthritis Center
University of Texas Southwestern Medical School

OFFICE ADDRESS: 5323 Harry Hines Blvd
Dallas TX 75390-8884

EDUCATION:

College: Brown University
Providence, Rhode Island 9/1969-6/1973
Sc.B. 1973, Biology

Professional or graduate: University of Chicago
Chicago, Illinois 10/1973 - 6/1977
M.S., Immunology
M.D.

Postgraduate Training: Intern, Internal Medicine 7/1977- 6/1978
Resident, Internal Medicine, 7/1978-6/1980
Medical College of Virginia
Richmond, Virginia
————— M.D., Chairman

Fellow, Rheumatology 7/1980-6/1983
University of Texas Southwestern Medical School
Dallas, Texas
————— Ph.D., M.D., Program Director

LICENSURE AND CERTIFICATION:

States in which licensed: Tennessee ———: expires 30 June 2009
Texas ——— expires 31 May 2008
Virginia ——— ; expires 30 June 2008

Specialty boards: American Board of Internal Medicine, ——— ; no expiration
9 September 1980

ABIM Rheumatology, ——— no expiration
9 November 1982

ACADEMIC APPOINTMENTS:

Instructor, Department of Medicine, 6/1983-12/1984
UT Southwestern Medical School

Assistant Professor of Medicine, 1/1985-11/1992
Vanderbilt University, Nashville TN

Associate Professor, Medicine, 11/1992-6/2000
Vanderbilt University, Nashville TN

Associate Professor, Microbiology&Immunology,1/1999-6/2004
Vanderbilt University, Nashville TN

Professor, Medicine, 6/2000-6/2004
Vanderbilt University, Nashville TN

Professor, Medicine 7/1/2004-
University of Texas Southwestern Medical School, Dallas TX

Program Director 07/01/2007-
Rheumatology Training Program
University of Texas Southwestern Medical Center, Dallas TX

HOSPITAL APPOINTMENTS:

Vanderbilt University Hospital, 1/1985-6/2004
Nashville VA Medical Center, 12/1985-
Courtesy Staff, Nashville Metro General Hospital, 1/1986-
6/2004
Parkland Hospital, 8/2004-
Zale-Lipshy University Hospital, 8/2004-
St. Paul University Hospital, 8/2004-

OTHER EMPLOYMENT:

Arthrochip, LLC – Chief Executive Officer
Franklin/Nashville, Tennessee

PROFESSIONAL ORGANIZATIONS:

American College of Rheumatology, Fellow
Inflammation Research Association
American Association of Immunologists
Southern Society for Clinical Investigation - elected 1995

PROFESSIONAL ACTIVITIES:

Intramural:

Committee on Admissions, 1989-2000
Vanderbilt University School of Medicine

Committee on Admissions: 1995-2000
Early Acceptance Subcommittee,
Vanderbilt University School of Medicine

Olsen, Nancy J.

Vanderbilt University Clinical Research Center Advisory Committee, 1992-1995; 2000-2004; Chairperson 2003-2004

Hospital Pharmacy Panel for Optimal Use of Intravenous Immunoglobulin - 1998

Residents Research Program Committee 1999-2003
Department of Medicine, Vanderbilt

_____ 2001-2004
Department of Medicine, Vanderbilt

Academic Support Services Committee: Six-Year Planning
UT Southwestern 2005-6; 2007-8

Extramural:

Study Sections

Arthritis Foundation Research Committee
Clinical Immunology Section, 1993-96

NIH-DRG Biochemical Endocrinology study section
ad hoc member, October, 1994

Special Review Panel, NIAMS, July 1997
SCORs in Scleroderma

Special Emphasis Panel Review Committee
NIH-NIAMS, October 29, 1999
NIAMS review of Arthritis Center Grants
January 4, 2001

Special Emphasis Panel Review Committee
"Sex-Based Differences in the Immune Response"
NIH/NIAID November 7-8, 2001
NIAMS review panel, SCORs in Systemic Lupus
April 11-12, 2002

NIH/NCI PO1 grant review Dana-Farber Institute, Boston MA,
October 10-11, 2002

NIAMS Special K24 Review Panel, Chair, January 2005

Allergy, Immunology and Transplantation Research Committee
NIH/NIAID member, 2002-2007; chair 2005-2007.

NIAMS/NIH Special Review P30 Applications

ZAR1 EHB-D (01), February 8, 2006

Alliance for Lupus Research
Grant Review Committee
November, 2006

NIAMS/P30 Rheumatic Diseases Research Core Centers
2007/05 ZAR1 KM-K (M1) (R)

Editorial activities

Editorial Board, *Arthritis and Rheumatism*, 1994-1997
Editorial Board, *Bulletin of the Rheumatic Diseases*, 2000-2004
Associate Editor, *Journal of Investigative Medicine*, 2004-
Associate Editor, *Arthritis Research & Therapy*, 2008-

Ad Hoc Reviewer:

Arthritis and Rheumatism
Arthritis Care and Research
Clinical Immunology and Immunopathology
Critical Care Medicine

Other professional activities:

Committees of the American College of Rheumatology:

Program/Abstract Selection Committee
Section Chair "Sjogren's Syndrome and Vasculitis"
Orlando Florida, October 1996

Program/Abstract Selection Committee
Member, "Rheumatoid Arthritis: Therapies"
Washington DC, November 1997

Program/Abstract Selection Committee
Member "Miscellaneous Rheumatic Diseases"
Boston MA, November 1999; San Francisco Oct. 2000

Program/Abstract Selection Committee
Section Chair "Miscellaneous Rheumatic Diseases"
Philadelphia PA, October 2000
San Francisco CA, October 2001

Ethics Committee, 1999-2002

Innovative Therapies Conference Planning Committee,
1999-2005

Olsen, Nancy J.

Abstract Reviewer, American College of Rheumatology
Annual Meeting, New Orleans, October 2002

Other extramural committees and activities:

Clinical Research Center Advisory Board
Meharry Medical College, Nashville, 1991 - 1994.

Program/Abstract Selection Committee
Southern Section, American Federation for Clinical Research
New Orleans LA, January 21-23, 1993.

Program/Abstract Selection Committee
Southern Section, American Federation for Clinical Research
New Orleans LA, February 1997.
Lupus Foundation of America, Nashville Chapter
Medical Advisory Board Chairman, 1998-2004

Councilor, Southern Society for Clinical Investigation
2000-2003

Southern Society for Clinical Investigation 2001
Lead Abstract Reviewer: Allergy/Immunology/Rheumatology

Examining Board Rheumatology
 American Board of Internal Medicine, 2000-2006

Data Safety and Monitoring Board - Member
 Gabapentin in the Treatment of Fibromyalgia
 University of Cincinnati
 NIH/NIAMS 2004-2007

Special awards or recognition for professional activities:

American Medical Women's Association Citation - 1977
Mary Roberts Scott Memorial Prize - 1977
Arthritis Foundation Postdoctoral Fellowship - 1982-1985
Senior Rheumatology Scholar Award - 1984
Arthritis Foundation Tennessee Chapter, Community Hero- 1998
Mary Eda Larsen Award, Lupus Foundation of America,
Nashville Chapter - 2001
Clinical Scholar Award, American College of Rheumatology
2003-2006

OTHER SIGNIFICANT ACTIVITIES:

Patent: U.S. Patent No. 5,616,458
 "Tripterygium Wilfordii Hook F Extracts and Components, and Uses
 Thereof" P Lipsky, X-L Tao, J. Cai, W. Kovacs, N.J. Olsen
 issued 1 April 1997.

Patent: U.S. Patent No. 5,846,742
"Selecting Substances for Treating Glucocorticoid-Mediated Inflammation or Immune Diseases using Tripterygium Wilfordii Hook F Extracts" P Lipsky, X-L Tao, J Cai, WJ Kovacs, NJ Olsen. issued 8 December 1998.

Patent: "Method for Predicting Autoimmune Diseases"
T. Aune, N. Olsen
Publication No. US-2003-0228617-A1, 11 December 2003, US Patent and Trademark Office

Provisional Patent Application No. 60/468,901 "A Gene Equation to Diagnose Rheumatoid Arthritis", N. Olsen, T. Aune, December 2003.

RESEARCH PROGRAM:

Peer-reviewed funding 1995-present (N. Olsen PI unless indicated):

NIDDK 2RO1 DK41053-04A1 "Effects of Androgens on the Thymus", 6/01/93 - 5/31/97; N.J. Olsen, P.I.; total direct costs \$340,173.

NIDDK 1 RO1 DK41042, POMC Peptide synthesis by Normal and AIDS Leukocytes. 2/01/89-1/31/92 PI: David N. Orth, MD.; direct costs \$270,000.

Arthritis Foundation Research Award "Studies of Inflammatory Myopathies with Magnetic Resonance Imaging and ³¹P Magnetic Resonance Spectroscopy," 07-01/91-06/30/94; direct costs \$: _____

Alpha Omicron Pi Foundation "Effects of Androgens on Immune Function," 07/01/92-03/31/93; direct costs \$: _____

University Research Council "Regulation of Thymic Development by Androgens in NOD Mice", 07/01/94 - 06/30/95; \$ _____

Lupus Foundation of America "Interruption of Intrathymic Androgen Signaling in NZB/W Mice", PI W. Kovacs; NJ Olsen, Consultant; 10/1/94 - 9/30/96 - \$ _____

NIAMS 1RO1AR43156-01 "Magnetic Resonance Imaging/Spectroscopy in Fibromyalgia", 09/30/94 - 09/29/97; total direct costs \$238,593.

NIDDK 5RO1 DK41053-08 "Effects of Androgens on the Thymus" 9/30/97 - 6/30/01; total direct costs \$496,827

NIAID 1R21 AI41575-01 "Effects of Androgens on B cell Development" 9/30/97-9/29/98; direct costs \$106,522

Olsen, Nancy J.

NIAID 1R01 AI41575-01A1 "Effects of Androgens on B Cell Development" 4/1/98-3/31/01; direct costs \$316,645; no cost extension 3/31/02.

NIH/NIAMS, Subcontract with University of Tennessee Medical Center, Memphis: "Type II collagen induction of Rheumatoid Arthritis patients off nonsteroidal-anti-inflammatory drugs" 8/1/99-7/31/04; direct costs requested \$203,643.

NIH/NIAMS Vascular Damage in SLE, C.M. Stein, P.I., N.J. Olsen, Co-I, 04/01/01-03/31/06; first year costs \$225,000.

NIH/NIAMS 5P30 AR41943-07 Skin Diseases Research Center, G. Stricklin, P.I., Pilot & Feasibility Project "Genetic Expression in SLE", P.I. T. Aune, Ph.D., Co-I N.J. Olsen, \$35,000 5/1/00 - 4/30/02.

VUMC Discovery Grant, W. Kovacs PI "Thymic Steroidogenesis" 1/1/01-12/13/02; \$ _____.

22. VUMC Discovery Grant, N. Olsen, PI, "Gene Expression in Systemic Lupus Erythematosus" 1/1/02-12/31/03, \$ _____

Vanderbilt Clinical Nutrition Research Unit, Pilot Grant, N. Olsen PI/consultant, "Treatment of Dermatomyositis with Creatine and Magnesium"; 11/1/02-10/31/04; \$ _____

CRC Pilot Grant, N. Olsen PI "Effects of Androgens on Immune Function" 1/1/03-12/31/03; \$ _____

NIH/NIAID 1 R41 AI053984, T. Aune PI, Arthrochip LLC "Gene Expression and Diagnosis of Autoimmune Disease" 2/15/03-2/14/04 \$133,756; N. Olsen PI on Vanderbilt subcontract. (Phase I STTR)

NIH/NIDDK 1 R41 DK65388-01, N. Olsen PI, Arthrochip LLC "Gene Expression and Diagnosis of Diabetes"; 09/01/03-08/31/04; \$119,957 (Phase I STTR) .

Clinician Scholar Educator Award, American College of Rheumatology, 07/01/2003-06/30/2006; \$ _____

NIH/NIAID 2 R42 AI053984, T. Aune PI, Archrochip LLC "Gene Expression and Diagnosis of Autoimmune Diseases" 7/1/04-6/30/06; Olsen consultant (Phase II STTR).

Lupus Clinical Trials Consortium, N. Olsen, Center Director, 01/15/2004-06/30/2004, \$ _____

NIH/NIDDK R42 DK65388, T. Aune, PI, Arthrochip LLC "Gene Expression and Diagnosis of Diabetes"; 07/01/05-06/30/07, \$750,000 total costs; Olsen PI on UTSW subcontract (Phase II STTR).

NIH/NIA 1R21 AG0276890-01, W. Kovacs PI, "Effects of Estrogens on T Cell Homeostasis"; 03/01/2007-02/28/2009, \$350,000 total costs; Olsen is co-investigator.

Olsen, Nancy J.

NIH/NIA 1R21 AG0276890-01, W. Kovacs PI, "Androgen Effects on T Cell Homeostasis in Older Men"; 04/01/2007-03/31/2009, \$314,000 total costs; Olsen is co-investigator.

NIH/NIAMS NOI-AR42273, C. Oddis, PI "Rituximab in Myositis"; 09/01/2005-08/31/2009; (Oddis); Clinical Site Agreement. Olsen is site PI.

NIH Contract No N01-AI-05419; K. Sullivan, PI Duke University; "A Randomized, Open-Label Phase II/III Multicenter Study of High-Dose Immunosuppressive Therapy using Total Body Irradiation, Cyclophosphamide and Autologous Transplantation Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis." 10/01/2006-09/21/2012; Clinical Site Agreement; Olsen is site PI.

NIH/NIAMS P50-AR055503-01 (Mohan); Center of Research Translation – Genetic Dissection of SLE – From Mouse to Man; 09/30/07 – 08/31/12. Roles: Co-PI of the CORT, Co-I Administrative Core, PI of Project 2: \$175,000 annual direct costs for Project 2.

Pharmaceutical/Industry support 1995-present:

_____ "A phase III double blind randomized placebo-controlled study to compare the activity and safety of _____ or placebo in subjects with active rheumatoid arthritis" 4/1/95-11/1/98; \$ _____ (direct)

_____ Research Institute: "A multiple intravenous infusion, randomized, double-blind, placebo-controlled study to determine the safety, tolerability, clinical activity, pharmacokinetics, and immunologic activity of multiple courses of _____ in rheumatoid arthritis patients" Protocol _____, 4/1/95-2/1/96; \$ _____ (total costs).

_____ Incorporated: "An Open-Label Multicenter Study to Evaluate the Safety and Tolerability of _____ in with Systemic Lupus Erythematosus"; 4/1/95-3/30/1999 \$ _____ (direct cost).

_____ "A Placebo-controlled, Double-blinded, Randomized Clinical Trial of _____ in Patients with Active Rheumatoid Arthritis _____, 4/1/97 - 6/30/00; total costs \$ _____.

_____ "A 24- week study to evaluate the safety and efficacy of _____ therapy in the _____ patients with active rheumatoid arthritis; direct costs \$ _____

_____ "A Double-Blind, Randomized, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of _____

_____ in Rheumatoid Arthritis Patients Treated Concurrently with Methotrexate." 6/1/96 - 12/31/97; _____

_____ “A randomized, double-blind, active and placebo-controlled, parallel group, dose response study of the anti-inflammatory activity, safety and pharmacokinetics of _____ in subjects with rheumatoid arthritis” 11/98 - 4/99; direct costs \$ _____

_____ Inc: “A double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of _____ in Rheumatoid Arthritis” Protocol _____, 1/98 - present; estimated direct costs \$ _____.

_____ “A Randomized, Double-Blind, Placebo-Controlled, _____ 1997-99 _____

_____ “A Pilot, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study To evaluate the Safety _____ Subjects with Rheumatoid Arthritis” 7/1/99 - 6/30/00; \$ _____ total costs.

_____ “A Phase II Randomized Double-Blind Placebo Controlled Study of the _____ on Rheumatoid Arthritis Patients _____ 9/1/99-8/31/01; \$ _____

_____ “Treatment of Systemic Lupus Erythematosus with _____; 8/1/00 – 2/004; \$ _____ total costs. Investigator-initiated single site.

_____ “A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Use Study to Evaluate the Safety and Tolerability of _____ Active Rheumatoid Arthritis” 2/1/03- 6/30/04; \$ _____

_____ 11/2004-present, estimated costs \$ _____ “A _____-week, double blind, randomized study _____ in subjects with active Rheumatoid Arthritis”;

_____ Autoimmune Diseases – Protocol _____ “A randomized, open-label, Phase II/III multi-center study of _____; 09/01/2006-; N. Olsen site PI.

_____ Maintenance Study”, 6/2005- present, \$ _____ (estimated).

_____ “A Phase I Randomized Double-Blind Placebo Controlled _____

Systemic Lupus Erythematosus with _____, 06/2006-06/2007, \$ _____ total costs.

Controlled Double-blind Parallel-group Multicenter Study to Evaluate the Safety and Efficacy of _____, 04/2006-present; \$ _____ estimated total costs.

PUBLICATIONS:

1. Articles in refereed journals 1995-present:

50. Park JH, Olsen NJ, King L, Vital T, Buse R, Kari S, Hernanz-Schulman M, Price RR: MRI and P-31 magnetic resonance spectroscopy detect and quantify muscle dysfunction in the amyopathic and myopathic variants of dermatomyositis. *Arthritis Rheum* 38:68-77, 1995.
51. Viselli SM, Stanziale S, Shults K, Kovacs WJ, Olsen NJ: Castration alters peripheral immune function in normal male mice. *Immunology* 84:337-342, 1995.
52. Viselli SM, Olsen NJ, Shults K, Stelzer G, Kovacs WJ: Immunochemical and flow cytometric analysis of androgen receptor expression in thymocytes *Mol Cell Endocrinol* 109:19-26, 1995.
53. Huang D-F, Siminovitch KA, Liu X-Y, Olee T, Olsen NJ, Berry C, Carson DA, Chen PP: Population and family studies of three disease-related polymorphic genes in systemic lupus erythematosus. *J Clin Invest* 95:1766-1772, 1995.
54. King LE Jr, Park JH, Adams LB, Olsen NJ: P-31 Magnetic resonance spectroscopy for quantitative evaluation of therapeutic regimens in dermatomyositis. *Archives Dermatol* 131:522-524, 1995.
55. Olsen NJ, Kovacs WJ: Testosterone treatment of systemic lupus erythematosus in a patient with Klinefelter's syndrome *American J Med Sci* 310:158-160, 1995.
56. Kari S, Olsen NJ, Park JH: Evaluation of muscle diseases using artificial neural network analysis of P-31 MR spectroscopy data *Magnetic Resonance in Medicine* 34:644-672, 1995.
57. Adams LB, Park JH, Olsen NJ, Gardner ES, Hernanz-Schulman M, King LE: Quantitative evaluation of improvement in muscle weakness in a patient receiving extracorporeal photopheresis for scleroderma: magnetic resonance imaging and magnetic resonance spectroscopy. *J Amer Acad Dermatol* 33:19-22, 1995.
58. Olsen NJ, Brooks RH, Cush JJ, Lipsky PE, St.Clair EW, Matteson EL, Gold KN, Cannon GW, Jackson CG, McCune WJ, Fox DA, Xoma RA Investigators group, Nelson B, Lorenz T, Strand V: A Double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis *Arthritis Rheum* 39:1102-1106, 1996.

60. Nakazawa M, Fantappie MR, Freeman GL, Eloi-Santos S, Olsen NJ, Kovacs WJ, Secor WE, Colley DG: Schistosoma mansoni: susceptibility differences between male and female mice can be mediated by testosterone during early infection. *Exper Parasitol* 85:233-240, 1997.
61. Olsen NJ, Viselli SM, Fan J, Kovacs WK: Androgens accelerate thymocyte apoptosis. *Endocrinology* 139:748-752, 1998.
62. Park JH, Phothimat P, Oates CT, Hernanz-Schulman M, Olsen NJ: Detection of metabolic abnormalities in muscles of patients with fibromyalgia using P-31 magnetic resonance spectroscopy *Arthritis Rheum* 41:406-413, 1998.
63. Viselli SM, Reese KR, Fan J, Kovacs WJ, Olsen NJ: Androgens alter B cell development in normal male mice. *Cell Immunol* 182:99-104, 1997.
64. Park JH, Kari S, King LE, Olsen NJ: Analysis of 31-P MR spectroscopy data using artificial neural networks for longitudinal evaluation of muscle diseases: Dermatomyositis. *NMR in Biomedicine* 11:245-256, 1998.
65. Park J, Bank W, Lech G, Long H, Olsen N, Chance B: Correlative magnetic resonance and near-infrared technologies for the evaluation of mitochondrial disease. *Biofactors* 7:253-254, 1998.
66. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, Fox R, Moreland L, Olsen N, Furst D, Caldwell J, Kaine J, Sharp J, Hurley F, Loew-Friedrich I: Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate. *Arch Int Med* 159:2542-50, 1999.
67. St. Clair W, Cohen S, Lee ML, Fleischmann RM, Lee SH, Moreland LW, Olsen NJ, Pratt PW, Yocum DE, Heck L, Winkelhake J, Holcenberg JS, Shulman MJ: Treatment of rheumatoid arthritis with a DR4/1 peptide. *Journal of Rheumatology*, 27:1855-63, 2000.
68. Park JH, Niermann KH, Ryder NM, Nelson AE, Das A, Lawton AR, Hernanz-Schulman M, Olsen NJ: Muscle abnormalities in juvenile dermatomyositis patients: P-31 magnetic resonance spectroscopy studies. *Arthritis Rheum* 43:2359-67, 2000.
69. Olsen NJ, Olson G, Viselli SM, Gu X, Kovacs WJ: Androgen receptors in thymic epithelium modulate thymus size and thymocyte development. *Endocrinology* 142:1278-1283, 2001.
70. Holla V, Adas F, Imig,JD, Zhao X, Price E, Olsen N, Kovacs WJ, Magnuson MA, Keeney DS, Breyer M, Falck JR, Waterman MR, Capdevila JH: Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenase cause hypertension. *Proc Natl Acad Sci U S A*. 98:5211-6, 2001.
71. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V: Two-year blinded randomized controlled treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. *Arthritis Rheum* 44:1984-1992, 2001.
72. Olsen NJ, Gu X, Kovacs WJ: Androgen-mediated suppression of B lymphocyte development: Role of stromal cells and transforming growth factor β . *J Clin Invest* 108:1697-1704, 2001.

73. Niermann KJ, Olsen N, Park JH: Magnesium abnormalities of skeletal muscle in dermatomyositis and juvenile dermatomyositis. *Arthritis Rheum* 46:475-488, 2002.
74. Moore JH, Parker JS, Olsen NJ, Aune T: Symbolic discriminant analysis of microarray data in autoimmune disease. *Genetic Epidemiol.* 23:57-69, 2002.
75. Maas, K, Chan S, Parker J, Slater A, Moore J, Olsen N, Aune TM: Molecular portrait of human autoimmune disease. *J. Immunol*, 169:10-14, 2002.
76. Kavanaugh A, Genovese M, Baughman J, Kivits A, Bulpitt K, Olsen N, Weisman M, Matteson E, Furst D, Van Vollenhoven R, Anderson J, Cohen S, Wei N, Meijerink J, Jacobs C, Mocci S. Allele and antigen-specific treatment of rheumatoid arthritis: a double blind placebo controlled phase 1 trial. *J. Rheumatol* 30:449-454, 2003.
77. Drake WP, Byrd VM, Olsen NJ: Reactivation of systemic lupus erythematosus after initiation of highly active antiretroviral therapy for acquired immunodeficiency syndrome. *J. Clin Rheumatol*, 9:176-180, 2003.
78. Reif DM, White BC, Olsen NJ, Aune TA, Moore JH: Complex function sets improve symbolic discriminant analysis of microarray data. *In: Lecture Notes in Computer Science*, 2724:2277-87, 2003.
79. Aune TM, Maas K, Moore JH, Olsen NJ: Gene expression profiles in human autoimmune disease. *Curr Pharmaceutical Design*, 9:1905-1917, 2003.
80. Asanuma Y, Oeser A, Shintani A, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM: Premature coronary artery atherosclerosis in systemic lupus erythematosus. *N Engl J Med* 349:2407-15, 2003.
81. Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, VanVollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. *Arthritis Rheum* 50:2858-2868, 2004.
82. Olsen NJ, Sokka T, Seehorn CL, Kraft B, Maas K, Moore J, Aune TM: A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. *Ann Rheum Dis*, 63:1387-92, 2004.
83. Aune TM, Parker JS, Maas K, Liu Z, Olsen NJ, Moore JH: Co-localization of differentially expressed genes and shared susceptibility loci in human autoimmunity. *Genetic Epidemiol*, 27:162-172, 2004.
84. Maas K, Westfall M, Pietenpol J, Olsen NJ, Aune T: Reduced p53 in peripheral blood mononuclear cells from patients with rheumatoid arthritis is associated with loss of radiation-induced apoptosis. *Arthritis Rheum* 52: 1047-1057, 2005.

85. Maas K, Chen H, Shyr Y, Olsen NJ, Aune T: Shared gene expression profiles in individuals with autoimmune disease and unaffected first-degree relatives of individuals with autoimmune disease. *Hum Mol Genet* 15:1305-1314, 2005.
86. Liu Z, Yelverton RW, Kraft B, Tanner SB, Olsen NJ, Aune TM: Highly conserved gene expression profiles in humans with allergic rhinitis altered by immunotherapy. *Clin Exp Allergy* 35:1581-90, 2005.
87. Olsen NJ: Tailoring arthritis therapy in the wake of the NSAID crisis. *N Engl J Med* 352:2578-2580, 2005.
88. Wandstrat AE, Carr-Johnson F, Branch V, Gray H, Fairhurst A-M, Reimold A, Karp D, Wakeland EK, and Olsen NJ. Profiling populations at risk for SLE. *J. Autoimmunity*, 27:153-160, 2006.
89. Li QZ, Zhou J, Wandstrat A, Carr-Johnson F, Branch V, Karp D, Mohan C, Wakeland EK, Olsen NJ. Protein Array Autoantibody Profiles for Insights into Systemic Lupus Erythematosus and Incomplete Lupus Syndromes. *Clin Exp Immunol* 147: 60-70, 2007.
90. Fossey SC, Vnencak-Jones CL, Olsen NJ, Sriram S, Garrison G, Deng X, Crooke PS, Aune TM: Identification of molecular biomarkers for multiple sclerosis. *J Molec Diagnostics* 9:197-204, 2007.
91. Olsen N. Anti-TNF switching: effect on outcomes in patients with RA. *Nat Clin Pract Rheumatol* 3:430-431, 2007.
92. Qi J, Olsen NJ, Price RR, Winston JA, Park JH: Diffusion-weighted imaging of inflammatory myopathies: polymyositis and dermatomyositis. *J Magn Reson Imaging*, 27:212-217, 2008.
93. Thudi A, Yin S, Wandstrat AE, Li QZ, Olsen NJ: Vitamin D levels and disease status in Texas patients with systemic lupus erythematosus. *Am J Med Sci* in press, 2008.

2. Books, book chapters, invited review articles (1995-present):

6. Olsen NJ, Park JH: Use of P-31 Magnetic resonance spectroscopy and near infrared spectroscopy for muscle disease evaluation. *Bull Rheum Dis* 44:4-7, 1995.
7. Viselli SM, Kovacs WJ, Le P, Itoh T, Thompson WD, Olsen NJ: Androgens and the thymus. *Allergy & Immunology (Life Sci. Adv.)* 14:21-19, 1995.
8. Olsen NJ: Practical problem: Polymyositis and Malignancy in: "Rheumatology", second edition, eds. J.H. Klippel and P.A. Dieppe, Mosby-Wolfe, London, UK. 1996.
9. Olsen NJ, King LE, Park JH: Muscle Abnormalities in Scleroderma. *Rheum Dis Clin North America*. 22:783-796, 1996.
10. Olsen NJ, Kovacs WJ: Gonadal Steroids and Immunity. *Endocrine Reviews* 17:369-384, 1996.

11. Olsen NJ, Wortmann R: Inflammatory and Metabolic Diseases of Muscle. *Primer on the Rheumatic Diseases*, 11th Edition. Arthritis Foundation, 276-282, 1997.
12. Olsen NJ, Park JH: Inflammatory Myopathies: Issues in Diagnosis and Management. *Arthritis Care and Research*, 10:200-207, 1997.
13. Olsen NJ, Park JH: Skeletal Muscle Abnormalities in Patients with Fibromyalgia. *Am J Med Sci* 315:351-358, 1998.
14. Cush JJ, Kavanaugh AF, Olsen NJ, Stein CM, Kazi S, Saag KG: Rheumatology Diagnosis and Therapeutics. Williams & Wilkins, Baltimore, 1998, 559 pp. [book].
15. Kovacs WJ, Olsen NJ: Sex Hormones and Immune Responses, in: *Contemporary Endocrinology: Autoimmune Endocrinopathies*, chapter 7, pages 163-181, R.Volpe, editor, Humana Press Inc., Totowa NJ, 1999.
16. Park JH, Olsen NJ: Diseases of Skeletal Muscle, in: *Skeletal Muscle Imaging for the Evaluation of Myopathies*, Chapter 16 pages 293-312, R.L.Wortmann, editor, Lippincott Williams & Wilkins, Philadelphia PA 1999.
17. Olsen NJ, Strand V, Kremer J: Leflunomide for the treatment of rheumatoid arthritis. *Bull Rheum Dis.* 48(8), 1999.
18. Olsen NJ: Idiopathic Inflammatory Myopathies. Scientific American Medicine/ Web MD 2000.
19. Park JH, Niermann KJ, Olsen NJ: Evidence for metabolic abnormalities in the muscles of patients with fibromyalgia. *Current Rheumatology Reports* 2000, 2:131-140.
20. Olsen NJ, Kovacs WJ: Hormones, Pregnancy and Rheumatoid Arthritis. *Journal of Gender-Specific Medicine.* 5(4), 2002.
21. Olsen NJ: Use of Biologic Agents in Rheumatoid Arthritis. *Journal of Musculoskeletal Medicine.* 19:487-496, 2002.
22. Park JH, Olsen NJ: Utility of magnetic resonance imaging in the evaluation of patients with inflammatory myopathies. *Current Rheumatol reports* 3:334-345.
23. Olsen NJ, Park JH, King LE: Amyopathic Dermatomyositis. *Current Rheumatol reports* 3:346-351.
24. Olsen NJ, Kovacs WJ: Effects of Androgens on T and B Lymphocyte Development. *Immunol. Research* 23:185-192, 2001.
25. Olsen, NJ: Dermatomyositis and Polymyositis. PIER, online publication of ACP/ASIM at <http://pier.acponline.org>; updated quarterly 2001-2004.

26. Olsen NJ, Kovacs WJ: Androgens in immunology and autoimmune diseases. Chapter in “Androgens and Androgen Receptor” C. Chang, editor, Kluwer Press, 2002.
27. Olsen NJ, Brogan BL: Drug-induced rheumatic syndromes. *Curr Opin Rheumatol* 15:76-80, 2003.
28. Olsen NJ, Brogan BL: Idiopathic Inflammatory Myopathies. Chapter 116 in “Scientific American Medicine”, D. C Dale and D. D. Federman, editors, 2003 Edition, WebMD Inc., New York NY, pages 1338-1345.
29. Aune TM, Maas K, Parker J, Moore JH, Olsen NJ: Profiles of gene expression in human autoimmune disease. *Cell Biochem Biophys* 40:81-96, 2004.
30. Olsen NJ, Stein CM: New Drugs for Rheumatoid Arthritis. *N Engl J Med* 350:2167-2179, 2004.
31. Olsen NJ, Moore JH, Aune TM: A gene expression signature for autoimmune disease in peripheral blood mononuclear cells. *Arthritis Res Ther* 6:120-128, 2004.
32. Olsen NJ: Drug-induced Autoimmunity. *Best Practice & Research Clinical Rheumatology*, 18:677-388, 2004.
33. Olsen NJ, Qi J, Park JH: Imaging and skeletal muscle disease. *Curr Rheumatol Reports* 7:106-114, 2005.
34. Olsen NJ, Orozco C: Defining the therapeutic significance of early RA diagnosis: Is remission possible? *J Musc Med*, 22:S6-S11, 2005.
35. Taurog JD, Olsen NJ: Morris Ziff, PhD, MD, 1913-2005, *Arthritis Rheum* 52:3323, 2005.
36. Orozco C, Olsen NJ: Identification of patients with early rheumatoid arthritis: Challenges and future directions. *Clin Dev Immunol*. 13:295-297, 2006.
37. Olsen NJ, Wandstrat AE, Karp DR: Profiling of risk for development of systemic lupus erythematosus. *Future Rheum*, 2:507-514, 2007.

Presentations 2006-2007:

Intramural at UTSW:

Medical Grand Rounds, UTSW: “Inflammatory Muscle Disease”, May 4, 2006

President’s Research Council, 2006: “Rheumatoid Arthritis: Can we make it disappear?” September 19, 2006.

Rheumatology Grand Rounds, UTSW: “Treatment of Scleroderma” October 5, 2006; “Sarcoidosis” March 22, 2007.

Olsen, Nancy J.

Extramural:

American College of Rheumatology, "Rheumatology at Meharry Medical College", Washington DC, November 2006.

Medical Grand Rounds, Providence Medical Center, Portland Oregon, "ANA: What it can and cannot do for you and your patients", February 21, 2007

American College of Rheumatology, Board Recertification Exam Preparation Course: "Rheumatoid Arthritis Diagnosis and Disease Manifestations", Philadelphia PA, March 17, 2007.

Dallas Internist's Club "CREST Syndrome" April 19, 2007.

UT Southwestern CME Course, Update in Rheumatology: "What's New in Lupus?", Irving TX 21 April 2007.

**APPEARS THIS WAY
ON ORIGINAL**